Treatment of short bowel syndrome patients with colon-in-continuity

Abstract

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.

What is claimed is: 
     
         1 . A method for treating an adult human patient with short bowel syndrome who is dependent on parenteral nutrition and who presents with colon-in-continuity with remnant small intestine, said method comprising administering to the patient [Gly2]hGLP-2 using a dosing regimen effective to reduce the dependency on parenteral nutrition by the patient. 
     
     
         2 . The method of  claim 1 , wherein the [Gly2]hGLP-2 is administered at a daily dose of from 5 to 500 μg/kg. 
     
     
         3 . The method of  claim 2 , wherein the [Gly2]hGLP-2 is administered at a daily dose of from 30 to 150 μg/kg. 
     
     
         4 . The method of  claim 1 , wherein the [Gly2]hGLP-2 is administered by subcutaneous injection. 
     
     
         5 . The method of  claim 4 , wherein the subcutaneous injection is into the abdomen, thigh, or arm. 
     
     
         6 . The method of  claim 1 , wherein the reduction on dependency is a decrease in the amount of parenteral nutrition received by the patient. 
     
     
         7 . The method of  claim 1 , wherein the reduction on dependency is a decrease in days or weeks of parenteral nutrition received by the patient. 
     
     
         8 . A method for treating an adult human patient with short bowel syndrome who is dependent on parenteral nutrition and who presents with colon-in-continuity with remnant small intestine, comprising administering to the patient [Gly2]hGLP-2 using a dosing regimen effective to reduce the dependency on parenteral nutrition by the patient; wherein the [Gly2]hGLP-2 is administered daily at a dose of from 30 to 150 μg/kg by subcutaneous injection into the abdomen, thigh, or arm. 
     
     
         9 . The method of  claim 8 , wherein the reduction on dependency is a decrease in the amount of parenteral nutrition received by the patient or a decrease in days or weeks of parenteral nutrition received by the patient. 
     
     
         10 . The method of  claim 1 , wherein said regimen comprises administration of said [Gly2]hGLP-2 over a period of at least 21 days. 
     
     
         11 . The method of  claim 8 , wherein said regimen comprises administration of said [Gly2]hGLP-2 over a period of at least 21 days.